Onegevity Health Partners with Gencove to Incorporate Sequencing into Its Consumer Health Intelligence Service

Onegevity Health, a new consumer health intelligence company, announced a partnership with Gencove, a leader in genome sequencing and analytics, to incorporate genome sequencing into its consumer health intelligence service.

Gencove will provide its cost-effective and scalable low-pass sequencing technology to support Onegevity Healths multi-omic artificial intelligence (AI) platform, consumer-friendly products, and digital services.

Onegevity Health delivers science-based recommendations for customized nutrition, clinically-studied supplements, and pre- and post-biotics to improve health outcomes. The companys first product, GutBioTM, combines its advanced Metagenome+TM sequencing technology with AI-based personalized insights and recommendations to help individuals manage and improve gut health. The partnership with Gencove will allow it to expand its offering to include genome sequencing.

Onegevity Health was founded by scientific pioneers Drs. Joel Dudley and Chris Mason, along with Thorne CEO Paul Jacobson. The partnership with Thorne will leverage the companys network of 35,000 physicians. Gencove was founded by leading scientists from the New York Genome Center.

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

Gencove and Onegevity Health also plan to leverage the growing multi-omics database for research and therapeutic development. Compared to other commonly used technologies in direct-to-consumer genomics such as genotyping arrays, Gencoves low-pass sequencing will integrate whole genome data, which in turn will accelerate research on rare genetic variants and early-stage drug target discovery.

According to Jacobson, Gencoves low-pass sequencing technologies provide us with the opportunity to apply genome sequencing at the scale necessary to truly impact population health and also ensure the greatest capacity to integrate future discoveries in all areas of the genome, from known genes to novel non-coding RNAs to regulatory regions, all of which are missed by vendors using arrays or exome capture. Also, genome-microbiome interactions can only truly be modeled by having such integrated data sets from each person.

Joe Pickrell, CEO and co-founder of Gencove, added, We are excited to support the scientific vision of Onegevity Health and its mission to improve consumer wellness.

About Onegevity Health

Based in New York, Onegevity Health delivers science-based, consumer-friendly recommendations for customized nutrition, clinically-studied supplements and pre- and pro-biotics to improve health outcomes. Onegevity provides a comprehensive molecular portrait and customized recommendations for an individuals health based on integrated analysis of longitudinal blood, genetics, and microbiome profiles. Onegevity leverages partner company Thornes network of 35,000 physicians to offer convenient testing and powerful analytical tools to improve preventative care and lower healthcare costs for their patients.

Brad Hennig
[email protected]
(415)
307-7856